Fund HoldingsFairmount Funds Management LLC

Total Portfolio Value
$1.51B
Total Bought
$35.00M
Total Sold
$202.67M
Net Transaction
-$167.67M
Filing Period:
Securities
SharesValue ($K)
Q1 2026
Q2 2026
Change
Q1 2026
Q2 2026
Weight (%)
Change
ORUKA THERAPEUTICS INC(ORKA)3,705,2623,705,2620181,743352,63023.31%+170,887
JADE BIOSCIENCES INC4,553,4944,553,494063,977101,1796.69%+37,202
DIANTHUS THERAPEUTICS INC(DNTH)2,537,1912,537,1910212,921247,32516.35%+34,404
ENLIVEN THERAPEUTICS INC1,855,6441,855,644072,74194,1746.22%+21,433
FAETH THERAPEUTICS INC(FTH)0722,020+722,020018,0511.19%+18,051
VIRIDIAN THERAPEUTICS INC(VRDN)3,914,4585,090,928+1,176,47076,56793,5206.18%+16,954
APOGEE THERAPEUTICS INC(APGE)298,647298,647025,13739,6392.62%+14,502
ZENAS BIOPHARMA INC(ZBIO)2,359,0252,359,025046,11959,8723.96%+13,753
INHIBIKASE THERAPEUTICS INC(IKT)8,625,0008,625,000014,49017,5091.16%+3,019
COGENT BIOSCIENCES INC(COGT)5,503,4185,503,4180211,827212,98214.08%+1,156
DAMORA THERAPEUTICS INC(DMRA)8,713,0008,713,0000225,667226,62514.98%+958
CRESCENT BIOPHARMA INC.(CBIO)2,747,8662,747,866050,47849,4623.27%-1,017
SPYRE THERAPEUTICS INC(SYRE)4,018,1010-4,018,101202,6730-202,673
Page 1 of 1
Fairmount Funds Management LLC — 13F Holdings — Q2 2026 | TickerTrail